Rapid Micro Biosystems delivers the Growth Direct System, an automated, non-destructive, rapid detection and enumeration technology based on the compendial method for microbial quality control in pharmaceutical manufacturing. The system automates and accelerates detection and enumeration in the areas of sterility testing, environmental monitoring, and bioburden testing, eliminating manual steps and analysis.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/26/13 | $32,600,000 | Series B |
Longitude Capital Quaker Partners TPG Biotech | undisclosed |
